Schonfeld Strategic Advisors LLC Buys New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Schonfeld Strategic Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,730 shares of the specialty pharmaceutical company's stock, valued at approximately $388,000.

A number of other large investors have also recently added to or reduced their stakes in SUPN. Smartleaf Asset Management LLC lifted its stake in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $52,000. Headlands Technologies LLC lifted its position in shares of Supernus Pharmaceuticals by 203.0% in the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $72,000. Finally, Venturi Wealth Management LLC purchased a new position in Supernus Pharmaceuticals during the 4th quarter worth approximately $92,000.

Supernus Pharmaceuticals Stock Down 2.3%

SUPN stock traded down $0.74 during trading hours on Wednesday, hitting $31.54. The company's stock had a trading volume of 423,213 shares, compared to its average volume of 492,906. The stock has a 50 day moving average price of $31.87 and a two-hundred day moving average price of $34.87. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The company has a market capitalization of $1.77 billion, a PE ratio of 29.48 and a beta of 0.74.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SUPN. StockNews.com lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This represents a 10.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.